Clinical trials
Immunotherapy clinical trials
Below are recruiting immunotherapy clinical trials, each written for real people, not researchers. We’re tracking 774 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06605833Enrolling by invitation
Heart health after immunotherapy for melanoma
This study looks at heart health in people who have finished immunotherapy for melanoma. It uses MRI scans to check for any heart problems that may have developed after treatment.
LondonAges 18 years+ - NCT06540508Enrolling by invitation
TACE with targeted immunotherapy for advanced liver cancer
This study looks at whether combining a liver-directed procedure called TACE with tiragolumab and targeted therapy works better for people with unresectable liver cancer that has not spread too far. Researchers will use blood and tissue tests to see how well the treatment works.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06303583Enrolling by invitationPhase 1/Phase 2
Chemo-radiation followed by immunotherapy for esophageal cancer
This trial tests if giving chemotherapy and radiation before surgery, followed by immunotherapy, can improve outcomes for people with a specific type of esophageal cancer that can be surgically removed.
Hangzhou, ZhejiangAges 18–75 - NCT06113315Enrolling by invitation
Collecting samples and data from sarcoma patients on immunotherapy
This study collects tissue samples and medical data from people with sarcoma who are receiving or will receive immunotherapy. Its goal is to learn more about how these treatments work against sarcoma.
Basking Ridge, New JerseyAges Any age - NCT05923216Enrolling by invitation
Testing oral sesame treatment to reduce severe reactions
This study tests an oral (mouth) sesame treatment designed to help the body stay “unresponsive” to sesame after treatment. If you previously took part in the earlier sesame study, this trial may help you see whether a sustained tolerance can be achieved and maintained.
WarsawAges 4–17 - NCT05350774Enrolling by invitationPhase 2
IV immunotherapy for lingering neurologic effects after COVID-19
This Phase 2 trial tests whether intravenous immunotherapy (IVIG) can improve ongoing neurologic symptoms after a mild-to-moderate COVID-19 illness. It targets people with persistent symptoms such as brain fog, fatigue, trouble thinking, dizziness when standing, and balance or other neurologic problems.
Bethesda, MarylandAges 18–100
Hear when a new Immunotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for immunotherapy?
- Yes. Clin2 currently lists 774 recruiting immunotherapy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a immunotherapy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a immunotherapy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.